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Abstract
The gut–liver axis is increasingly considered to play a vital part in the progression of chronic inflammatory gut and liver
diseases. Hence, a detailed understanding of the local and systemic regulatory mechanisms is crucial to develop novel
therapeutic approaches. In this review, we discuss in-depth the roles of regulatory T cells (Tregs) and mucosal-associated
invariant T cells (MAITs) within the context of inflammatory bowel disease, primary sclerosing cholangitis, and non-
alcoholic steatohepatitis. Tregs are crucial in maintaining peripheral tolerance and preventing autoimmunity. MAIT cells
have a unique ability to rapidly recognize microbial metabolites and mount a local immune response and act as a ‘biliary
firewall’ at the gut and biliary epithelial barrier. We also outline how current knowledge can be exploited to develop novel
therapies to control the propagation of chronic gut- and liver-related inflammatory and autoimmune conditions. We
specifically focus on the nature of the Tregs’ cell therapy product and outline an adjunctive role for low-dose IL-2. All in
all, it is clear that translational immunology is at crucial crossroads. The success of ongoing clinical trials in cellular
therapies for inflammatory gut and liver conditions could revolutionize the treatment of these conditions and the lives of
our patients in the coming years.
Keywords Regulatory T cells  Mucosa associated invariant T cells (MAIT)  Non-alcoholic steatohepatitis 
Inflammatory bowel disease  Gut and liver axis  Cell therapy
Introduction
The gut–liver axis is considered to play a key role in
immune-mediated diseases such as autoimmune sclerosing
cholangitis/primary sclerosing cholangitis (AISC/PSC) and
inflammatory bowel disease (IBD). The underlying causes
of these diseases and their progression are multifactorial as
the gut comprises a unique microbiome, ingested nutrients,
the mucosal immune system as well as the gut—portal vein
barrier [1–4]. As there is yet no effective therapeutic for
both IBD and AISC, patients can develop intestinal failure,
colonic malignancy and in cases of AISC, the disease
progresses to fibrosis, cirrhosis and hepatocellular carci-
noma (HCC) and cholangiocarcinoma [3–5]. Hence, it is
more important than ever to understand the gut–liver axis,
and in particular, targeted anti-inflammatory pathways.
The role of regulatory T cells (Tregs) has been exten-
sively explored in autoimmune-mediated inflammatory gut
and liver diseases such as IBD and AISC/PSC, albeit
mainly within pre-clinical settings [6–10]. Tregs are crucial
in preventing autoimmunity as they have an anti-
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inflammatory property that can suppress effector T-cell
subsets [11]. Additionally, alongside Tregs, there are other
immune cells in the gut and liver microenvironments such
as myeloid-derived suppressor cells and tolerogenic den-
dritic cells that could also provide a similarly beneficial
anti-inflammatory function.
Mucosal-associated invariant T cells (MAIT cells),
which are a mucosa T-lymphocyte subset in humans
[12–14], are characterized by the expression of a conserved
Va7.2 chain and CD161 receptor expression, but are
restricted by the major histocompatibility complex class
1-related molecule (MR1) [13, 15]. This is important as it
infers that MAIT cells are evolutionarily evolved T-cell
subsets that have the capacity to directly recognize a nar-
row repertoire of bacterial-derived vitamin B metabolites
[12]. Additionally, their location in the gut mucosa and
continuity with the biliary epithelium are especially perti-
nent as these are the two sites of bacterial entry into the gut
and liver microenvironments [13].
Gut–liver axis
Due to its unique embryonic development, the human liver,
which originates from the endoderm, is connected to the
gut via both the biliary tracts and portal vein. As a result of
the multiple localized components of the gut (e.g., micro-
biome, nutrients, metabolites, mucosal immunity, and gut–
portal vein barrier), it has not always been possible to
identify and dissect a specific cause of immune-mediated
chronic inflammatory gut and liver disease processes [1, 2].
More importantly, as the liver is the first recipient of these
gut-sourced components, any homeostatic alteration in the
profile of these gut components can directly impact the
liver’s own homeostatic physiological processes [1, 3].
When one considers the multiple functions of the liver
(e.g., glucose homeostasis, lipid transport, protein synthesis
as well as immune surveillance), it is comprehendible how
the gut can impact both hepatic and systemic physiology.
The gut microbiome has more than a trillion microbes
that chiefly comprise three bacterial phyla: Bacteroidetes,
Actinobacteria, and Firmicutes [1, 3]. Whilst these phyla
exist in individual-specific proportions in healthy individ-
uals, their altered proportions have been reported in a
number of patients with chronic inflammatory gut and liver
diseases [1, 3, 16]. For example, in patients with non-al-
coholic steatohepatitis (NASH), a condition closely asso-
ciated with obesity, an inverted Bacteroidetes/Firmicutes
ratio has been reported compared to those obese patients
without NASH [5, 17]. Importantly, whether this dysbiosis
is a cause or effect of inflammatory gut/liver disease is yet
unknown. These microbes are responsible for digesting
dietary polysaccharides to form monosaccharides, free
fatty acids (FFAs) such as acetate, propionate, and butyrate
as well as reactive oxygen species (ROS) and ethanol as
by-products [1, 17]. The parallel effects of ROS and
ethanol interfere with mucosal parenchymal and immune
cell function through oxidative stress and damage the tight
junctions that enclose the intestinal epithelial layer, which
increases intestinal permeability. This increased intestinal
permeability allows for further diffusion of danger-asso-
ciated molecular patterns (DAMPs), FFAs, ROS across the
epithelial layer and into the portal venous supply [3, 18].
The intraportal translocation of these molecules to the liver
and subsequent transmigration along the sinusoids provides
chronic inflammatory stimulus. It is this induced inflam-
matory process that interferes with the liver’s parenchymal
and immune cell functions and thereby, propagates chronic
liver disease.
Conceptually, it is vital to keep in mind that although
the liver is the destination of gut-sourced compounds, the
liver itself can also influence gut-absorptive function
through both primary and secondary bile acids, bile salts
and immunoglobulins secretion [19, 20]. Bile acids act via
the farsenoid X receptor (FXR) to alter gene expression of
intracellular programs responsible for inflammation as well
as metabolism of bile acids, glucose, cholesterol, and lipids
[20]. This has implications for gut microbes as it alters
substrate availability for metabolism, and thereby alters
their own ability to metabolize polysaccharides as descri-
bed above. Additionally, liver-secreted immunoglobulins
(e.g., IgA) are responsible for forming a protective biofilm
that reinforces the intestinal epithelial layer [21]. Hence,
any hepatic pathology can lead to alterations in the secre-
tion of biliary acids and immunoglobulins and conse-
quently, impact gut function.
Regulatory T cells
Thymic Tregs are a subset of CD4 T cells that are char-
acterized by high-level expression of interleukin-2 receptor
alpha chain (CD25) and low expression of interleukin-7
receptor alpha chain (CD127) [22, 23]. Thus,
CD4?CD25?CD127low is the typical phenotype of thy-
mic Tregs. Treg also expresses the Forkhead Box P3
(Foxp3) transcription factor, which is a master regulator of
Treg development and function [24, 25]. Indeed, such is its
importance that loss of Foxp3 is associated with the
development of the autoimmune syndrome; IPEX (immune
dysfunction, polyendocrinopathy, enteropathy, and
X-linked) in humans and the scurfy phenotype in mice
[26, 27].
Tregs exist as two main subsets within the peripheral
microenvironment; thymus-derived (tTregs) and peripher-
ally induced Tregs (pTregs) [28, 29]. The tTregs mature in
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the thymus and exit into the peripheral circulation as bona
fide Tregs (Foxp3?); however, the pTregs are derived from
differentiated CD4?CD25?Foxp3- T cells upon T-cell
receptor (TCR) stimulation in the presence of transforming
growth factor beta (TGF-b) and interleukin-2 (IL-2)
[28, 29]. Both subsets have been identified in the gut and
liver and both exhibit immunosuppressive and homeostatic
functions [8, 30, 31]. However, to exhibit these functions in
their respective microenvironments, Tregs express che-
mokine receptors, which facilitate their migration and
homing to the specific and relevant tissue directed by the
corresponding chemokines which act as postcodes for the
receptors. For example, CCR9/a4b7 and CCL25/MadCAM
for gut homing, CXCR3 and CXCL9-11 for inflammatory
liver diseases and specifically, CCR9, aEb7, CCL25/E-
cadherin in AISC and PSC [6, 8, 9, 32]. Indeed, we have
shown that inflamed liver sinusoids have increased
expression of CXCR3 ligands such as CXCL9 and
CXCL10 which further facilitate recruitment of CXCR3
expressing Tregs to control the hepatic inflammatory
response [6]. Tregs remain as the main regulatory immune
cells to maintain hepatic tolerance, which they achieve
through a range of functional markers such as CTLA-4,
CD39, LAG-3 and secretion of IL-10 amongst others
[33, 34] (Fig. 1).
Although there have been extensive pre-clinical studies,
the in vivo Treg mechanisms of action remain undefined.
The current consensus is that Tregs utilize multiple
mechanisms to perform their functions [35, 36]. For a
detailed overview of these mechanisms, we refer you to
excellent reviews by Miyara et al. and Sakaguchi et al.
[35, 36].
MAIT cells
MAIT cells are found in abundance within peripheral tis-
sues such as the gut and liver; however, their exact roles in
the pathogenesis of autoimmune-related diseases in these
compartments have not been fully elucidated [15, 37, 38].
MAIT cells are defined as CD3?, Va7.2?, CD161? T
lymphocytes (Fig. 2) [39, 40]. Human MAIT cells are
predominantly of the CD8? effector memory phenotype.
Although double-negative MAIT cells (CD4- CD8-) are
present in modest numbers and the CD4? T lymphocytes
make up only a minority of this subset in the peripheral
circulation, the relative proportions of MAIT cells alter in
chronic liver disease [15, 39, 41]. This diversity leads
further credence to their differing roles in the microenvi-
ronment depending on their phenotype.
Bacteria, yeast and viruses can all stimulate a MAIT
cell-mediated effector response through their DAMPs
[42, 43]. This role of DAMPs in patients with inflammatory
gut and liver disease is evidenced by their increased levels
both in the inflammatory microenvironment and peripheral
blood [44–46]. In particular, Kjer-Nielson et al. showed
that products of bacteria-derived vitamin B2 metabolism
(riboflavin metabolites) could be presented to Va7.2
expressing MAIT cells in an MR1-dependent manner by
antigen-presenting cells (APCs) such as monocytes, den-
dritic cells and B cells [12]. These APCs could have been
infected by variety of bacteria and fungi, including My-
cobacterium tuberculosis, Salmonella typhimurium,
Escherichia coli, Staphylococcus aureus and Candida
albicans [43]. This presentation would lead to activation of
MAIT cells and triggers a prompt inflammatory response
Fig. 1 Tregs are recognized as CD4?CD25?CD127low (extracellu-
larly) and Foxp3? (intracellularly). They express a range of other
phenotypic markers such as TIGIT (T-cell immunoreceptor with Ig
and ITIM domains), Helios, LAP (latency-associated peptide), GARP
(glycoprotein A repetitions predominant), GITR (glucocorticoid-
induced tumor necrosis factor receptor-related protein), HLA-DR,
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), CD73, CD39
and CXCR3. Upon activation, Tregs release interleukin-10 (IL-10)
and interleukin 35 (IL-35)
Fig. 2 Intrahepatic MAIT cells are characterized by expression of
CD3?, TCR Va7.2, and CD161. Their characteristic intracellular
markers are Tbet, RORcT, and PLZF. They also express a range of
receptors and markers as visualized in this figure. Upon activation,
MAIT cells release the cytokines TNFa, IFNc, and IL-17. They can
also release granzymes and perforin
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by cytokines, granzymes secretion, and degranulation;
thereby eradicating the early localized infection [47].
Interestingly, MAIT cells do not recognize all bacteria,
prime examples being Enterococcus faecalis, Listeria
monocytogenes and Group A streptococcus, implicating
these strains lack the ability to produce the relevant
DAMPs [43].
MAIT cells can also be activated in MR1-independent
manner by viruses (e.g., hepatitis C (HCV), influenza and
dengue) through the interleukin receptors IL12R and
IL18R which are present on their cell surface [48]. Their
effector response was evidenced by upregulation of gran-
zyme B expression. Interestingly, patients with hepatitis C
receiving pegylated interferon (IFN-a) as part of their
treatment regime demonstrated increased MAIT cell
expression of the activation marker CD69 which was
associated with a higher sustained virologic response
(SVR) as well. This indicates that MAIT cell activity may
enhance the host immune response to this virus.
Intracellularly, MAIT cells express several transcription
factors, most notably retinoic acid-related orphan receptor
gamma t (RORcT), which controls IL-17 production and
T-bet, which controls TNFa and IFNc secretion [49].
MAIT cells also possess a set of homing chemokine
receptors (CCR2, CCR5, CCR6, CCR9 and CXCR6),
which enable their recruitment or ‘trafficking’ to specific
sites of inflammation [49]. Upon activation, MAIT cells
produce TNFa, IFNc, IL-2, IL-17 and release cytotoxic
granzymes and perforin, which rapidly induce cytolysis
and death of target cells [49].
Inflammatory bowel disease (IBD)
The role of Tregs has been extensively studied in IBD
[8, 9]. This is an autoimmune condition predominantly of
the gut characterized by dysregulation of the mucosal
immune system [9, 50, 51]. This condition is pertinent to
the gut–liver axis as approximately 66–75% of PSC
patients will also develop IBD [40, 52]. Whilst the
underlying reasons for this cross-over are unknown, it
potentially indicates molecular mimicry between gut-
specific and biliary-specific immune cells. Additionally,
there may be a role for bi-directional trafficking of pro-
inflammatory immune cells between the gut and liver.
Indeed, if true, this would complement novel findings from
our department describing the role of gut-homing memory
mucosal lymphocytes, albeit within the context of PSC
[53–55]. Hence, any therapy in IBD/PSC must traffic to
two different tissue sites to achieve disease control.
From an IBD pathogenesis perspective, gut barrier
dysfunction in IBD facilitates increased exposure of bac-
terial products to local and lymphatic APCs, which
propagates a local inflammatory response consisting of
effector T cells (Th1, Th2 and Th17) and Tregs [56, 57].
The role of Tregs is pertinent as although they are found
within the gut mucosa of healthy patients, they exist in
higher levels in the inflamed tissue of patients with IBD
[58]. Additionally, studies have reported these Tregs to be
less functional than those of healthy patients, which have
implications for their ability to control the local inflam-
matory response [9, 58].
Tregs in IBD have been studied through multiple murine
models of colitis such as chemically induced (e.g., dextran-
sulfate sodium and TNBS) and transgenic (e.g., IL-2 and
STAT3 KO) [59, 60]. These models have been critical in
demonstrating that adoptive transfer of Tregs can abrogate
colonic inflammation [60]. Depending on the model used,
the underlying mechanisms have been purported to involve
Treg contact with pro-inflammatory APCs in the gut lymph
nodes and IL-10 secretion [8, 51, 59].
Hence, this role of Tregs as having anti-inflammatory
potential in IBD could be harnessed in the form of a cel-
lular therapy to treat IBD patients with disease refractory to
current medical regimens [9, 61]. Additionally, as there is
yet no specific antigen which is known to initiate or
propagate the pathogenesis of IBD, the Treg cellular
therapy product will best be better suited to an autologous
polyclonal version. However, one must be mindful as to the
relative efficacy of polyclonal Tregs as opposed to gut
‘antigen-experienced’ Tregs [62]. Work by Canavan et al
showed expanded blood derived naı¨ve Tregs (CD4?CD2
?CD127loCD45R?) maintained their Foxp3 expression
and could considered as the ‘most appropriate population’
to use in a trial for IBD as they remain lineage stable fol-
lowing expansion [61]. This was on the basis of stable ex-
pression of the Foxp3 gene (key for Treg function and
development), CCR7 and a4b7 (gut-homing markers).
They are presently undertaking the TRIBUTE trial to
investigate Treg therapy in Crohns’ disease
(NCT03185000).
Interestingly, in IBD, MAITs are found to be decreased
in number in the blood, but increased at sites of inflam-
mation such as the ileum in Crohns’, thus supporting the
concept of cell trafficking. MAITs are, however, also found
in the lamina propria of healthy individuals [41, 63]. Some
investigators observed that MAITs in IBD patients were
expressing higher levels of caspase, which indicate their
apoptotic nature within this disease [12, 64]. Whether this
results from cellular exhaustion following activation and is
an anergic phenotype or reflects cellular dysfunction is
presently under investigation by our group.
Additionally, cytokines, chemokines, and metabolites
within the gut microenvironment can further facilitate
favorable conditions for activation of MAITs. This is
important as the intestinal mucosa of patients with Crohn’s
308 Hepatology International (2018) 12:305–314
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is abundant in IL-12 and IL-18, which enables MAIT-cell
activation in MR1-independent manner [41]. Upon acti-
vation, MAITs are capable of releasing inflammatory
cytokines such as IFNc. However, patients with Crohn’s
have an altered cytokine production upon activation;
involving decreased IFNc and increased IL-17 [65].
Whether these findings are incidental descriptive observa-
tions or demonstrate a direct role for MAITs in Crohn’s is
yet unknown. Intriguingly, recent reports comment on a
protective role of IL-17 in the intestinal mucosa [66]. This
was clearly demonstrated in a clinical trial of secukinumab,
an anti-IL-17 antibody whose administration resulted in
exacerbation and flare-up of Crohn’s in patients [63, 65].
Put together, perhaps this altered cytokine production in
IBD reflects the fact that during chronic inflammation, the
production of IL-17 by MAIT cells together with other IL-
17 producing immune cells provides attenuation of the
inflammatory activity operating, therefore, as part of the
body’s immune resolution mechanism to control the
disease.
In general, patients with IBD have an altered gut
microbiome [67]. This is potentially pertinent to MAITs
are they are activated by bacteria and fungi that produce
ligands of the riboflavin synthetic pathway. MAITs can
recognize ligands presented by APCs infected by a variety
of microbes, including M. tuberculosis, S. typhimurium,
E. coli, S. aureus, and C. albicans. Importantly, not all
bacteria have the capacity to activate MAIT cells: Ente-
rococcus faecalis, Listeria monocytogenes and Group A
Streptococcus do not activate MAIT cells, suggesting these
strains lack the offending antigen [15, 49, 68]. Hence, we
would hypothesize that gut dysbiosis can directly alter
MAIT-cell function [37]. A study by van Wilgenburg and
colleagues demonstrated MAIT cell activation in the blood
from patients infected with HCV, dengue virus and influ-
enza infection [48]. This line of inquiry is presently under
investigation by our group to dissect the gut–liver axis.
Biliary and gut epithelial immunity
The portal vein is the main mode of transport of gut-
derived antigens, endotoxins and nutrients to the liver [69].
Indeed, the gut and liver need to be able to differentiate
continuously between self- and non-self-antigens to main-
tain tolerance. At the same time, both organs have to
rapidly respond to an array of potentially pathogenic
microbes to mount the immune response. The direct link
between the gut and liver is attributed to have a potential
causal role into why IBD patients commonly also have
PSC [40, 52]. Although there are multiple animal models to
study each condition in isolation, the respective animal
models to accurately reflect dual pathologies concomitantly
are still under development [70].
As the liver is the first destination of all gut-derived
compounds, the liver’s Kupffer cells have been referred to
as a vascular ‘firewall’ that protects the host against gut and
biliary epithelial DAMP exposure [49]. Our group has
demonstrated that MAIT cells are found predominantly
around the intrahepatic bile ducts in the vicinity of the
portal tracts [71]. This finding was seen both in healthy
‘donor’ livers and explanted livers from patients with
inflammatory liver diseases. Additionally, the MAIT cells
from the latter group of patients actively secreted TNFa,
IL-17 and produced granzyme B when bacteria were pre-
sented via MR1 to Va7.2 expressing intrahepatic antigen-
presenting B cells (Fig. 3). We thus proposed that intra-
hepatic MAIT cells are ideally located to act not only as
part of the firewall conferring protection around in the
portal tract, but as a ‘biliary firewall’ by protecting
ascending infection via biliary tree [13]. This immuno-
surveillance function in the liver is an orchestrated effort
not only by intrahepatic MAIT cells, intrahepatic Tregs and
Kupffer cells, and dendritic cells, but also by the vast array
of fast-acting immune surveillance cells such as the natural
killer cells, innate lymphoid cells, and gamma delta T cells
[72, 73]. Additionally, we demonstrated that biliary
epithelial cells (BEC) are able to act as ‘‘non-professional’’
APCs when exposed to E. coli and subsequently activate
MAIT cells in MR1-dependent manner and secrete
cytokines and perform degranulation [71] (Fig. 3). These
crucial findings provide further evidence that MAIT cells
have the capacity to safeguard the biliary mucosa, which is
in direct continuity with the gastrointestinal tract and
constant exposure to its microbiome.
NASH
NASH is a chronic inflammatory liver condition that can
progress to fibrosis, cirrhosis and even HCC [74, 75]. This
condition is pertinent to the gut–liver axis as its develop-
ment is intrinsically linked to a high-fat diet and dysbiosis
of the gut microbiome [1, 3]. The high level of fat in the
western diet leads to hepatic steatosis and thereby changes
the make-up of nutritional substrates available for local
cellular metabolism [76–78]. This has direct consequences
for Treg function as Tregs intrinsically rely on fatty acid
oxidation as their main pathway for adenosine triphosphate
(ATP) production [79].
Moreover, the severity of NASH directly correlates with
an inverted Th17/Treg ratio [77, 80]. This is augmented by
a pro-inflammatory cytokine profile consisting of increased
local levels of IL-6, IL-17, 21–23 [80]. Studies in NASH
patients who undergo extensive weight loss have
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demonstrated reduced levels of Th17 cells, increased Tregs
and IL-10 levels [80, 81]. Whether these findings are
coincidental or directly indicate a role for Th17 cells and
Tregs in NASH is unknown. Due to the recent surge in
metabolic surgery for NASH patients, we anticipate further
evidence in future for the immunological mechanisms
driving improvements in fatty liver disease and other
components of the metabolic syndrome.
From the perspective of the gut microbiome, patients
who develop NASH exhibit an inverted Bacteroidetes/
Firmicutes phyla ratio compared to those only on a high-fat
diet [1, 3]. This is important as the NASH patients exhibit a
‘leaky gut’ which leads to exposure of an altered DAMPs
profile to the gut mucosal immune system as well as the
hepatic immune system through intraportal uptake [44].
These DAMPs can directly impact on Tregs through the
TLR receptors [82]. This is supported by novel data from
mouse models demonstrating a pivotal mechanism between
TLR signaling, Foxp3 expression and subsequent Treg
metabolism and function [83]. Stimulation of TLR1/2
increases proliferation of Tregs through glycolysis, but
reduces their suppressive capacity. However, Foxp3
expression does not promote glycolysis and increases the
Treg suppressive capacity instead. The detailed roles of
DAMPs on Tregs metabolism and function remain an
ongoing line of inquiry in our group.
Clinical translation
Tregs and MAITs have very distinct functions within the
gut and liver and these functions could be synergistically
exploited to achieve inflammatory disease control either in
the gut mucosa or intrahepatic environment or around the
peri-biliary region (Fig. 3). Indeed, Tregs on their own are
already undergoing evaluation as a therapeutic cellular
option for a range of inflammatory and autoimmune con-
ditions within the context of early-phase clinical trials
[30, 84–87]. Our group too has recently completed its own
phase-1 safety trial involving polyclonal Tregs in autoim-
mune hepatitis (manuscript in press). However, from the
perspective of chronic hepatic viral infections, it is
Fig. 3 Demonstrating the MR1-restricted presentation to MAITs by
biliary epithelial cells (BECs) and how Tregs could potentially
interfere with this process. The BECs act as ‘non-professional’ APCs
as they possess the MHC Class 1-like molecule, MR1. MR1 restricts
the Va7.2 T-cell receptor on intrahepatic MAIT cells to microbial-
derived vitamin B metabolites. Upon activation, MAIT cells release
the cytokines TNFa, INFc, IL-17 and the degranulating proteins;
granzymes and perforin. We hypothesize that Tregs can interfere with
either MAITs or BECs or both with resulting effects on the activation
status of MAITs. This will have implications for the roles of Tregs as
anti-inflammatory cells and MAITs as anti-microbial responders. The
exact mechanisms of this interaction are currently under investigation
by our group
310 Hepatology International (2018) 12:305–314
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anticipated that inhibition of Treg function could be a
potential therapeutic approach instead [88, 89]. Patients
with chronic hepatitis B (HBV) and HCV have higher
levels of Tregs in comparison to controls with treated
disease [88, 89]. These Tregs have been found to inhibit
CD4? and CD8? effector T-cell responses, thus limiting
in vivo infection resolution. However, successful transla-
tion of this approach in the hepatic viral setting has been
limited by suboptimal understanding of the complex
mechanisms underlying interactions between Tregs,
effector T cells and APCs in the hepatic viral setting [88].
Nevertheless, in future, we anticipate greater clarity on
the optimal dosing, safety and efficacy profile of Tregs in
humans. As it is being explored for other conditions, the
nature of Tregs could be polyclonal, antigen-specific,
genetically modified (chimeric-antigen receptor; CAR, T
cell receptor gene transfer), Foxp3 (Tr1 cells) or tissue site-
specific (CCR7/a4b7 or CXCR3 Treg) [61, 86, 90, 91]. It is
likely that the final Treg product will differ depending on
the disease pathology as certain autoimmune conditions
already have identified autoantigens whereas others remain
unknown (e.g., autoimmune hepatitis type 1 vs type 2) [6].
The advantage of a known autoantigen is that investigators
could manufacture a tailored patient-specific and disease-
specific product with CAR T cells or CAR Treg therapy as
they are more potent, thus requiring fewer cells numbers
and prevent global immune suppression. However, inves-
tigators will need to weigh this up against the costs of
obtaining a sufficient cell yield, processing time and pro-
curement costs along with the regulatory process to
ascertain that they fulfill the requirements of a safe inves-
tigational medicine product (IMP).
In parallel, there will also be optimization of existing
Treg isolation and expansion protocols under good manu-
facturing practice (GMP) conditions [61, 91–93]. This is
important as current protocols use different pharmacolog-
ical agents to maximize Treg yield and function (e.g., IL-2,
rapamycin, retinoic acid, and activator beads) [92–94]. In
particular, the inclusion of low-dose IL-2 is advantageous
as it is crucial for Treg survival and function [95, 96].
Clinical trials in graft versus host disease (GVHD) and
vasculitis using low-dose IL-2 as a stand-alone therapy for
inflammatory and autoimmune conditions have already
demonstrated increased Treg survival in these conditions
and reduced disease activity [95–98]. Our group has
recently reported that low-dose IL-2 clinical grade can
enhance Treg function in a CTLA-4-dependent manner
[95]. Thus, the combination of Tregs and very low-dose IL-
2 could be a potentially valuable therapeutic option. This
would also provide an optimal microenvironment to pro-
vide lineage stability of administered Tregs to prevent them
from converting to pro-inflammatory effector T cells [99].
We anticipate that this will be crucial for inflammatory
liver diseases particularly as work from our group has
demonstrated their livers to be deficient in IL-2 and enri-
ched with pro-inflammatory cytokines [34].
In comparison to Tregs, the field of MAIT cell as a
translational therapeutic application remains in its infancy
and certainly, their detailed site-specific mechanisms of
action still need to be delineated before therapeutic appli-
cation. It is likely that the presence of MAITs in the gut and
biliary epithelium facilitates their ability to rapidly recog-
nize and respond to the increased exposure to bacterial-
derived vitamin B metabolites, whose increased levels are
a direct consequence of the ‘leaky gut’ [37]. Patients with a
‘leaky gut’ have an increased DAMPs load both locally and
in the peripheral blood, which facilitates increased recog-
nition of vitamin B metabolites [100]. MAITs can mount a
pro-inflammatory response against these bacterial-derived
vitamin B metabolites to inhibit the direct effects of bac-
teria themselves on other immune and parenchymal cells.
In the case of viral infections, the work by van Wilgenburg
et al. supports a role for MAIT cells in response to HCV
[48]. MAIT cells were activated upon acute HCV infection
in vitro in a dose-dependent manner and in those patients
on treatment for chronic HCV; increased MAIT cell acti-
vation was also identified upon treatment initiation. These
activated cells inhibited replication of HCV in an IL-18-
dependent manner alongside IL-12 and crucially in
response to interferon alpha (IFN-a). Importantly, IFN-a is
a key therapeutic in HCV treatment regimens and its ability
to promote MAIT-cell activation may be one of the
mechanisms underlying its therapeutic role. Overall, the
combination of anti-microbial effector function of MAIT
cells and the anti-inflammatory effects of Tregs could be
exploited in parallel to ameliorate the propagation of
chronic inflammatory gut and liver diseases (Fig. 3).
Conclusion
The role of the gut–liver axis in propagating a number of
inflammatory gut and liver pathologies has fascinated both
clinicians and scientists. Due to the multifactorial nature of
the contribution by immune cells, microbiome, diet,
metabolites, and predisposition of genetic profile, the dis-
section of the pathologies is more challenging. However,
the identification of crucial immunological mechanisms is
a vital step in developing novel therapeutics. Tregs play a
crucial role in preventing autoimmunity and regulating the
local inflammatory microenvironment and MAITs have a
role in anti-microbial immunity at the biliary and gut
epithelial layers, which are consistently exposed to
microbial stimulation, thus both cell types could be
exploited synergistically to regulate the gut–liver axis.
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The holy grail remains the successful translation of this
acquired knowledge to develop novel cellular therapy
products and control the progression of inflammatory and
autoimmune gut and liver diseases. Tregs on their own are
already the subject of clinical trials by investigators
worldwide. Indeed, there has never been a more exciting
time to be involved in the development of cellular therapies
for gut and liver diseases. The success of this novel cellular
therapy approach could radically alter the therapeutic
options available to clinicians and transform the lives of
our patients.
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